Search the Newsreel

Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates

Zimmer Biomet (ZBH) reported strong Q2 results, with earnings of $2.07 per share and revenues of $2.18 billion, both exceeding Zacks Consensus Estimates. The company has consistently surpassed EPS estimates over the last four quarters and revenues three times. Despite underperforming the market year-to-date, …

Zimmer Biomet Q2 Adjusted Earnings Flat, Net Sales Rise; Lifts 2026 Guidance

Zimmer Biomet Holdings reported flat adjusted earnings for Q2 2026 but saw an increase in net sales. The company also raised its 2026 financial guidance following strong implant demand. Several analysts have adjusted their price targets for Zimmer Biomet in response to the earnings …

Zimmer Biomet’s (NYSE:ZBH) Q2 CY2026: Beats On Revenue

Zimmer Biomet (NYSE:ZBH) reported better-than-expected revenue in Q2 CY2026, with sales up 4.8% year-on-year to $2.18 billion, beating analyst estimates. The company's non-GAAP profit of $2.07 per share also surpassed estimates by 3%, and management slightly raised its full-year Adjusted EPS guidance. While the …

AC Immune’s Parkinson’s Trial Gets a $4 Million Grant

AC Immune (NASDAQ: ACIU) reported its first-half 2026 financial and corporate update, highlighting a $4 million grant for its Phase 2 VacSYn trial (ACI-7104) for Parkinson’s disease. The company also received a $12 million milestone payment from Takeda for initiating a new cohort in …

Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA

The article focuses on the "Price to book forward" metric for Estrella Immunopharma, Inc. (NASDAQ: ESLA), a health technology and biotechnology company. It presents a snapshot of the company's financial overview within the TradingView platform, noting that the market was closed at the time …

Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss

Press Release: Zimmer Biomet Announces Second Quarter 2026 Financial Results

Zimmer Biomet announced its financial results for the second quarter of 2026. The company is providing a press release detailing its performance for the quarter. This release will offer insights into the company's financial health and operational achievements.

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

Zimmer Biomet (NYSE: ZBH) lifts Q2 2026 earnings and cash flow

Zimmer Biomet Gets FDA 510(k) Clearance for Next-Gen ROSA Shoulder System

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW

Pomerantz LLP has filed a class action lawsuit against Immunovant, Inc. (formerly Health Sciences Acquisitions Corporation) and some of its officers, seeking to recover damages for investors who purchased Immunovant securities between October 2, 2019, and February 1, 2021. The lawsuit alleges that Immunovant …

IMUX Technical Analysis & ETF Price Forecast

The article provides a technical analysis of Immunic, Inc. (IMUX), indicating a "Neutral" sentiment based on various technical indicators. While some moving averages suggest a "Buy" signal given the current share price of $14.05, momentum indicators like RSI and MACD are currently neutral. The …

Edgestream Partners L.P. Makes New $1.31 Million Investment in Immunome, Inc. $IMNM

Edgestream Partners L.P. has made a new $1.31 million investment in Immunome, Inc. (NASDAQ:IMNM), acquiring 59,888 shares. This investment highlights continued institutional interest, with other hedge funds also adjusting their positions, bringing total institutional ownership to 44.58%. Despite analyst recommendations for a "Moderate Buy" …

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) reported a Q2 loss of $0.08 per share, surpassing the Zacks Consensus Estimate of a $0.09 loss and showing an 11.11% earnings surprise. The company also beat revenue estimates, posting $51.24 million against an estimated $48.45 million. ImmunityBio's stock has seen a …

LEG Immobilien SE (LEGIF) (H1 2026) Earnings Call Highlights: Resilient Rent Growth and ...

This article first appeared on GuruFocus. Release Date: August 04, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Like-for-like rent growth of 3.7% in H1 2026, within the full-year guidance corridor, with 50 …

ImmunoPrecise Antibodies Ltd. (NASDAQ: HYFT) Stock Price, News & Analysis

Insider at IMNM (NASDAQ: IMNM) plans sale of 90,616 shares

Alfred K. Horn, an insider at Immunome Inc. (NASDAQ: IMNM), has filed a Form 144 notice to sell up to 90,616 shares of common stock on August 4, 2026, through Fidelity Brokerage Services LLC. This planned sale is in connection with a stock option …

Zimmer Biomet (NYSE: ZBH) exec vests 9,957 RSUs, with 4,266 shares withheld

Kevin R. Thornal, Group President-Global Business at Zimmer Biomet Holdings, Inc. (NYSE: ZBH), exercised 9,957 Restricted Stock Units (RSUs) into common stock on August 1, 2026. To cover tax obligations, 4,266 shares were withheld at $92.68 per share. Following this transaction, Thornal holds 19,913 …

Zimmer Biomet faces earnings test as growth questions persist

Zimmer Biomet is set to report its second-quarter earnings, with investors focused on whether its strategic transformation, including sales force restructuring and robotics investments, is accelerating growth. Analysts expect earnings of $2.01 per share on revenue of $2.14 billion, with organic growth remaining a …

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday

Lyell Immunopharma (NASDAQ:LYEL) is expected to announce its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $2.0243 per share and $5,000 in revenue. Despite a consensus "Moderate Buy" rating and a target price of $43.20, the …

BMNR Stock Tracks Ethereum Surge As Staking And Buybacks Ramp

BitMine Immersion Technologies (BMNR) stock has seen a 3.97% surge, primarily driven by its significant Ethereum holdings and staking activities through its MAVAN platform. The company controls about 4.8% of the total ETH supply, generating substantial annualized staking revenues, and is undertaking a $4B …

Immunitybio Inc earnings missed by $0.14, revenue topped estimates

Immunitybio Inc (NASDAQ: IBRX) reported second-quarter EPS of $-0.22, missing analyst estimates by $0.14. However, the company's revenue of $51.24M surpassed the consensus estimate of $47.22M. The stock has seen a significant increase of 196.68% over the last 12 months, despite a recent 7.86% …

ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings

Persimmon Plc Revenue Breakdown – LSE:PSN

IMVT Maintained by JP Morgan -- Price Target Raised to $50.00

JP Morgan has maintained an Overweight rating on Immunovant (IMVT), increasing its price target to $50.00 from $47.00. Despite this positive analyst outlook, Immunovant holds a low GF Score™ of 29/100, indicating challenges in profitability and growth, and has seen significant insider selling. The …

ImmixBio plans one-on-one investor meetings in New York Sept. 14-16

Immix Biopharma (Nasdaq: IMMX) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026, where it will host one-on-one investor meetings. The company will discuss its lead AL Amyloidosis CAR-T candidate, NXC-201, which has received FDA Breakthrough Therapy, …

Bitmine Accelerates Stock Buybacks And Continues Buying Ethereum

Bitmine Immersion Technologies (NYSE: $BMNR) has accelerated its stock buybacks even as it continues making weekly purchases of Ethereum (CRYPTO: $ETH). The company led by Chairman Tom Lee has increased its $4 billion U.S. share repurchase program, buying back 4.5 million BMNR shares over …

IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales

ImmunityBio (IBRX) reported record second-quarter revenue of $51.2 million, surpassing Wall Street estimates, largely driven by strong sales of its cancer therapy, Anktiva. Despite a wider net loss due to non-cash accounting charges, Chairman Patrick Soon-Shiong highlighted the company's focus on expanding Anktiva's applications …

Immix Biopharma Announces Participation in Morgan Stanley 24th Annual Global Healthcare Conference and Institutional Investor Meetings

Immix Biopharma (IMMX) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026, where it will host meetings with institutional investors. The company, a leader in treating relapsed/refractory AL Amyloidosis, will discuss its lead CAR-T cell therapy, NXC-201, …

ImmunityBio Releases Q2 2026 Financial Results

ImmunityBio, Inc. (IBRX) reported a net loss of $230.4M and a loss per share of $0.22 for Q2 2026, widening from Q2 2025 as the company invests in its immunotherapy platform. Despite increased losses, revenue grew significantly to $51.2M, up 92.0% year-over-year, driven by …

ImmunityBio, Inc. (IBRX) Q2 2026 Earnings

ImmunityBio, Inc. (IBRX) reported its Q2 2026 earnings, with an EPS of -$0.22 against an estimated -$0.08, and revenue of $51M, exceeding the $50M estimate. The company's ANKTIVA revenue saw a 94% year-over-year increase, marking its eighth consecutive quarter of sequential gains. The EPS …

Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M

ImmunityBio, Inc. (IBRX) reported Q2 revenue of $51.2 million, surpassing the FactSet estimate of $49.7 million. This earnings flash indicates stronger-than-expected revenue performance for the biotechnology company in the second quarter.

ImmunityBio Q2 revenue rises 92% to record $50.7 million

ImmunityBio (IBRX) reported a significant increase in Q2 2026 total revenue, reaching $51.2 million, with net product revenue up 92% year-over-year to a record $50.7 million. The company's ANKTIVA product continues to drive growth, marking its eighth consecutive quarter of sequential revenue increase, and …

Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX)

ImmunityBio (NASDAQ: IBRX) reported record Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase, and $94.8 million for the first half of 2026. Despite this revenue growth, the company experienced a higher GAAP net loss of $230.4 million in Q2 and …

Interest Rates Could Lift These US Regional Bank Stocks

This article identifies three US regional bank stocks—Metropolitan Bank Holding (MCB), Simmons First National (SFNC), and First Merchants (FRME)—that could benefit from rising interest rates due to their loan books and deposit bases being highly sensitive to rate changes. It details each bank's operations, …

Altimmune (ALT) Projected to Release Quarterly Earnings on Tuesday